BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 28, Issue 8
  • This Article
Peer-Review Report of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©The Author(s) 2022.
World J Gastroenterol. Feb 28, 2022; 28(8): 775-793
Published online Feb 28, 2022. doi: 10.3748/wjg.v28.i8.775
Table 5 Use of anti-hyperglycaemic agents in cirrhotic individuals according to Child-Pugh class[102]
Drug
Child-Pugh class A
Child-Pugh class B
Child-Pugh class C
Short-acting insulins
HumanAllowedAllowedAllowed (dose reduction)
LysproAllowedAllowedAllowed
AspartAllowedAllowedAllowed
GlulisineAllowedAllowedAllowed
Long-acting insulins
Human-NPHAllowedAllowedAllowed (dose reduction)
GlargineAllowedAllowedAllowed
LevemirAllowedAllowedAllowed
DegludecAllowedAllowedAllowed
Glargine-300AllowedAllowedAllowed
Sulfonylureas
GlibenclamideNot recommendedContraindicatedContraindicated
GlimepirideAllowed (caution)Not recommendedContraindicated
GliclazideAllowed (caution)Not recommendedContraindicated
GlipizideAllowed (caution)Not recommendedContraindicated
Meglitinides
RepaglinideAllowed (caution)Not recommendedContraindicated
Biguanides
MetforminAllowedAllowed (dose reduction)Contraindicated
Thiazolidinediones
PioglitazoneAllowedContraindicatedContraindicated
DPP-4 inhibitors
SitagliptinAllowedAllowedContraindicated
VildagliptinContraindicatedContraindicatedContraindicated
SaxagliptinAllowedAllowedContraindicated
LinagliptinAllowedAllowedContraindicated
AlogliptinAllowedAllowedContraindicated
GLP-1RAs
ExenatideAllowedContraindicatedContraindicated
LiraglutideAllowedContraindicatedContraindicated
LixisenatideAllowedAllowedContraindicated
Exenatide LARAllowedAllowedContraindicated
DulaglutideAllowedAllowedContraindicated
SemaglutideAllowedAllowedContraindicated
α-glicosidase inhibitors
AcarboseAllowedAllowed (caution)Contraindicated
SGLT2 inhibitors
DapaglifozinAllowedAllowedContraindicated
CanaglifozinAllowedAllowedContraindicated
EmpaglifozinAllowedAllowedContraindicated
ErtugliflozinAllowedAllowedContraindicated
DPP-4: Dipeptidyl peptidase 4; GLP-1 RAs: Glucagon-like peptide 1 receptor agonists; SGLT2: Sodium-glucose cotransporter 2; NPH: Neutral protamine Hagedorn; LAR: Long-acting release.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.